Agenus shared a post on LinkedIn:
“Today we announced that Agenus has triggered the first $20M contingent payment under our strategic collaboration with Zydus Group, supporting manufacturing activities for botensilimab (BOT) and balstilimab (BAL).
As enrollment advances in the BATTMAN Phase 3 trial, reimbursed access continues in France under the AAC framework, and named patient programs expand in select countries, aligning manufacturing capacity with anticipated demand is essential.
Read the full announcement.”
Other articles from Agenus on OncoDaily.